Clinuvel Europe Limited

6 trials 1 recruiting Commercial sponsor Merged from 2 name variants

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

1 Recruiting

3 Completed trials

6 Countries active

1 Unique IMPs

100% Results reported

Phase II/III

Phase II

Phase I/II

Phase II/III: 1 Phase II: 4 Phase I/II: 1

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Parkinson's disease 2 Ischaemic stroke 1 Vitiligo 1

Top IMPs

AFAMELANOTIDE 6

All trials

6 total

A Phase IIa, Open Label Study to Evaluate the Safety of Afamelanotide in Patients with Early Parkinson's Disease Not authorised

2022-502207-30-00 Phase II 1 country AFAMELANOTIDE
A Mechanistic Study to Evaluate Impact of Afamelanotide in Aqueous Solution on Ultraviolet Radiation-Induced DNA Damage and DNA Repair Capac… Pending

2023-505907-21-00 Phase II 1 country AFAMELANOTIDE
A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versu… Recruiting

2023-507470-40-00 Phase II/III 2 countries AFAMELANOTIDE
A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients with Erythropoietic Protoporphyria (EPP). Ended

2023-507311-35-00 Phase I/II 2 countries AFAMELANOTIDE
Phase IIa Aqueous Afamelanotide Solution Stroke Study Ended

2022-500919-40-01 Phase II 1 country AFAMELANOTIDE
A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients with Early Parkinson's Dise… Ended

2022-502207-30-01 Phase II 1 country AFAMELANOTIDE

Showing 1–6 of 6 trials

← All sponsors A–Z